(Reuters) – An experimental drug first and necessary being developed to handle influenza is showing promise in opposition to SARS-CoV-2 and would perchance well protect in opposition to COVID-19 from two diversified instructions, researchers stated.
The drug, known as zapnometinib or ATR-002, would perchance well doubtlessly curb the proliferation of the virus in cells and likewise lower the exaggerated immune response that contributes to essential illness in severe cases of COVID-19, take a look at tube experiments indicated.
The information, printed in Mobile and Molecular Life Sciences, equipped the premise on which the German Institute of Medication and Medicinal Merchandise gave manufacturer Atriva Therapeutics its recognition of the drug to be tested in folk, the researchers stated.
This marks the first time any drug has been shown to possess a dual action in opposition to COVID-19, stumble on co-author Stephan Ludwig of the College of Muenster stated in a information free up. “Sure results from the still-ongoing scientific stumble on in humans would perchance well already consequence in an emergency approval this twelve months,” Ludwig stated.
SOURCE: https://bit.ly/33lZSWn Mobile and Molecular Life Sciences, online January 10, 2022.
